Skip to content
ppharmaranks
Menu

Best treatments for urinary bladder neoplasms (bladder cancer)

17 products may treat urinary bladder neoplasms (also known as bladder cancer), spanning FDA drug classes such as programmed death receptor-1 blocking antibody, interleukin-15 receptor agonist, topoisomerase inhibitor. The current highest-rated option is keytruda. Ranked below by our independent recall-safety rating (rated where FDA data exists) — not medical advice; always consult a professional.

Quick answer: Of the 17 drugs we list for urinary bladder neoplasms, none are yet flagged as generics in our price data, spanning classes such as programmed death receptor-1 blocking antibody, interleukin-15 receptor agonist, topoisomerase inhibitor. 4 of 17 carry a safety score, from 72 to 72 out of 100. They’re ranked by each drug’s FDA recall-safety record — not clinical effectiveness for urinary bladder neoplasms — so confirm the right choice with your prescriber.

Rated against independent regulatory sources·Last updated October 10, 2026·How we rate

Understanding urinary bladder neoplasms

Bladder cancer is a cancer that begins in the cells lining the bladder, the organ that stores urine. According to the National Cancer Institute (NCI), the most common symptom is blood in the urine, called hematuria, which is often slightly rusty to bright red in color. Other symptoms can include frequent urination, pain or burning during urination, feeling as if you need to urinate even when the bladder isn't full, and urinating often during the night. NCI notes these symptoms can also be caused by non-cancerous conditions such as urinary tract infections or kidney or bladder stones, and advises checking with your doctor if you have any of them. To diagnose bladder cancer, NCI describes checking a urine sample in the lab for blood, abnormal cells, or infection; urine tumor marker tests; imaging such as a CT urogram; and cystoscopy, in which a lighted instrument is inserted through the urethra to view inside the bladder. A biopsy taken during cystoscopy is examined by a pathologist under a microscope to confirm cancer. Management depends on whether the cancer is non-muscle-invasive or muscle-invasive and on its stage. This is general information, not medical advice.

First-line treatment

Per the National Cancer Institute (NCI) and the American Cancer Society (ACS), there is no single first-line treatment. ACS states that treatment is based mainly on the clinical stage of the cancer when first diagnosed, and that other factors, such as tumor grade, size, and number, the person's overall health, and their preferences, are also important. Categories of treatment described by NCI include surgery (such as transurethral resection or bladder removal), chemotherapy (intravesical or systemic), immunotherapy (including BCG placed in the bladder), radiation therapy, and targeted therapy; clinical trials may also be an option. NCI states that you and your cancer care team work together to decide your treatment plan, which may include more than one type of treatment. The specific plan is individualized by an oncology team for each patient based on stage and tumor characteristics. This is general information, not medical advice.

Top-rated picks for urinary bladder neoplasms: 1. Keytruda · 2. Opdivo · 3. Padcev

Top-rated treatments for urinary bladder neoplasms, ranked by pharmaranks score
#DrugRatingPharmacy pays
172/100—View →
272/100—View →
372/100—View →
472/100—View →
5Not yet rated—View →
6Not yet rated—View →
7Not yet rated—View →
8Not yet rated—View →
9Not yet rated—View →
10Not yet rated—View →

Full ranking · 17 treatments

MERCK SHARP DOHME logo

keytruda

PrescriptionFDA-sourced

72/100

Keytruda (Pembrolizumab) is a programmed death receptor-1 blocking antibody used to treat Malignant Mesothelioma, Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Non-Small-Cell Lung Carcinoma.

(4 data points)
programmed death receptor-1 blocking antibodymesothelioma, malignantbiliary tract neoplasms

Price varies

View details →
BRISTOL MYERS SQUIBB logo

opdivo

PrescriptionFDA-sourced

72/100

Opdivo (Nivolumab) is a programmed death receptor-1 blocking antibody used to treat Urinary Bladder Neoplasms, Non-Small-Cell Lung Carcinoma, Squamous Cell Carcinoma, Kidney Neoplasms.

(5 data points)
programmed death receptor-1 blocking antibodyurinary bladder neoplasmscarcinoma, non-small-cell lung

Price varies

View details →

padcev

Boxed warning

PrescriptionFDA-sourced

72/100

Padcev (Enfortumab Vedotin-Ejfv) is a medication used to treat Urinary Bladder Neoplasms.

(5 data points)
urinary bladder neoplasms

Price varies

View details →

tecentriq

PrescriptionFDA-sourced

72/100

Tecentriq (Atezolizumab) is a medication used to treat Urinary Bladder Neoplasms, Non-Small-Cell Lung Carcinoma, Hepatocellular Carcinoma, Melanoma.

(11 data points)
urinary bladder neoplasmscarcinoma, non-small-cell lungcarcinoma, hepatocellular

Price varies

View details →

anktiva

PrescriptionFDA-sourced

New

Anktiva (Nogapendekin Alfa Inbakicept-Pmln) is an interleukin-15 receptor agonist used to treat Urinary Bladder Neoplasms.

interleukin-15 receptor agonisturinary bladder neoplasms

Price varies

View details →
AVYXA HOLDINGS logo

avopef

PrescriptionFDA-sourced

New

Avopef (Etoposide) is a topoisomerase inhibitor used to treat Urinary Bladder Neoplasms, Brain Neoplasms, Lung Neoplasms, Mycosis Fungoides.

topoisomerase inhibitorurinary bladder neoplasmsbrain neoplasms

Price varies

View details →

Frequently asked

What is the best medication for bladder cancer?
bladder cancer is urinary bladder neoplasms. There isn't a single "best" medication for everyone — Per the National Cancer Institute (NCI) and the American Cancer Society (ACS), there is no single first-line treatment. ACS states that treatment is based mainly on the clinical stage of the cancer when first diagnosed, and that other factors, such as tumor grade, size, and number, the person's overall health, and their preferences, are also important. Categories of treatment described by NCI include surgery (such as transurethral resection or bladder removal), chemotherapy (intravesical or systemic), immunotherapy (including BCG placed in the bladder), radiation therapy, and targeted therapy; clinical trials may also be an option. NCI states that you and your cancer care team work together to decide your treatment plan, which may include more than one type of treatment. The specific plan is individualized by an oncology team for each patient based on stage and tumor characteristics. This is general information, not medical advice.. Compare every option ranked above by our independent recall-safety rating (not an efficacy measure); this is general information, not medical advice.
What treats urinary bladder neoplasms?
Our catalog lists 17 products that may treat urinary bladder neoplasms, based on NIH RxClass (MED-RT “may treat”) drug-classification data — not the verbatim FDA label. They're rated where FDA recall-safety data exists; the current top-rated option is keytruda.
What is the best-rated treatment for urinary bladder neoplasms?
By our independent recall-safety rating — not an efficacy measure — keytruda ranks highest among the products we list for urinary bladder neoplasms. Always consult a professional.
How are these treatments ranked?
By our independent score, currently based on FDA regulatory recall-safety data (the methodology blends additional sources as they come online). See the How we rate page.
What types of drugs treat urinary bladder neoplasms?
Treatments for urinary bladder neoplasms span FDA drug classes including programmed death receptor-1 blocking antibody, interleukin-15 receptor agonist, topoisomerase inhibitor, platinum-based drug, anthracycline topoisomerase inhibitor. Compare every option side by side, ranked by independent rating, above.

Treatment associations are derived from NIH RxClass (MED-RT “may treat”) drug-classification data — not the verbatim FDA label. This is general reference, not medical advice — always consult a licensed professional.

Sources

The clinical overview above is written from these authoritative public-health and medical-society sources, independently reviewed against each.